Chloroquine use improves dengue-related symptoms

Memorias do Instituto Oswaldo Cruz

Volumn 108, Issue 5, 2013, Pages 596-599

  Borges, Marcos Carvalho ^a   Castro, Luiza Antunes ^a   da Fonseca, Benedito Antonio Lopes ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Activities of daily living; Chloroquine; Dengue; Therapeutics

Indexed keywords

ANTIVIRUS AGENT; CHLOROQUINE;

ADULT; ANALGESIA; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; METHODOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CHLOROQUINE; DENGUE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PAIN MANAGEMENT; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879572897     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762013000500010     Document Type: Article

References (26)

1. Adachi K, Ichinose T, Takizawa N, Watanabe K, Kitazato K, Kobayashi N 2007. Inhibition of betanodavirus infection by inhibitors of endosomal acidification. Arch Virol 152: 2217-2224.
2. AlKadi HO 2007. Antimalarial drug toxicity: a review. Chemotherapy 53: 385-391.
3. Castro-Jorge LA, Machado PR, Favero CA, Borges MC, Passos LM, de Oliveira RM, Fonseca BA 2010. Clinical evaluation of the NS1 antigen-capture ELISA for early diagnosis of dengue virus infection in Brazil. J Med Virol 82: 1400-1405.
4. Di Trani L, Savarino A, Campitelli L, Norelli S, Puzelli S, D'Ostilio D, Vignolo E, Donatelli I, Cassone A 2007. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J 4: 39.
5. Dussart P, Labeau B, Lagathu G, Louis P, Nunes MR, Rodrigues SG, Storck-Herrmann C, Cesaire R, Morvan J, Flamand M, Baril L 2006. Evaluation of an enzyme immunoassay for detection of dengue virus NS1 antigen in human serum. Clin Vaccine Immunol 13: 1185-1189.
6. Gandini M, Reis SRNI, Torrentes-Carvalho A, Azeredo EL, Freire MS, Galler R, Kubelka CF 2011. Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-α and IFN-α profiles. Mem Inst Oswaldo Cruz 106: 594-605.
7. Hober D, Poli L, Roblin B, Gestas P, Chungue E, Granic G, Imbert P, Pecarere JL, Vergez-Pascal R, Wattre P 1993. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 48: 324-331.
8. Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH 1989. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 40: 418-427.
9. Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P 2009. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53: 3416-3421.
10. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV 1992. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol 30: 545-551.
11. Lindenbach BD, Rice CM 2003. Molecular biology of flaviviruses. Adv Virus Res 59: 23-61.
12. Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, Desai SN 2010. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother 54: 871-881.
13. Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi PY 2010. Strategies for development of dengue virus inhibitors. Antiviral Res 85: 450-462.
14. Pinheiro FP, Corber SJ 1997. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World Health Stat Q 50: 161-169.
15. Pinto LMO, Oliveira SA, Braga ELA, Nogueira RMR, Kubelka CF 1999. Increased pro-inflammatory cytokines (TNF-a and IL-6) and anti-inflammatory compounds (sTNFRp55 and sTNFRp75) in Brazilian patients during exanthematic dengue fever. Mem Inst Oswaldo Cruz 94: 387-394.
16. Randolph VB, Winkler G, Stollar V 1990. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174: 450-458.
17. Rolain JM, Colson P, Raoult D 2007. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30: 297-308.
18. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R 2003. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 3: 722-727.
19. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A 2006. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6: 67-69.
20. Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, Morra E, Tamburrini E, Perno CF, Boelaert JR, Sperber K, Cauda R 2004. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 35: 223-232.
21. Schatzmayr HG 2000. Dengue situation in Brazil by year 2000. Mem Inst Oswaldo Cruz 95 (Suppl. I): 179-181.
22. Taylor WR, White NJ 2004. Antimalarial drug toxicity: a review. Drug Saf 27: 25-61.
23. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, Tran HT, Simmons CP 2010. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 4: e785.
24. Tutor-Ureta P, Yebra-Bango M 2005. Antimalarials in systemic diseases. Rev Clin Esp 205: 230-232.
25. Valero N, Levy A 2008. Future prospects in developing of dengue vaccines. Invest Clin 49: 135-138.
26. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST 2005. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2: 69.